This is the classic website, which will be retired eventually. Please visit the modernized instead.

Key Record Dates Identifier: NCT05646862
Brief Title: A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121)

First Submitted : December 2, 2022
First Submitted that Met QC Criteria : December 2, 2022
First Posted : December 12, 2022

Last Update Submitted that Met QC Criteria : January 31, 2024
Last Update Posted : February 1, 2024